Non-invasive muscle contraction assay to study rodent models of sarcopenia

BMC Musculoskeletal Disorders

Hilary A Wilkinson³  Osvaldo Flores³  Gary Kath²  Stephen E Alves³  Michael A Gentile³  Albert Rauch¹  Sharon Adamski³  Hans Weber³  Chi-Sung Chiu³ 

[1] Research Operations, Merck Research Laboratories, West Point, Pennsylvania 19486, USA;Research Operation, Merck Research Laboratories, Rahway, New Jersey 07065, USA;Department of Molecular Endocrinology, Merck Research Laboratories, West Point, Pennsylvania 19486, USA

关键词: castration.;    dexamethasone;    Boltzmann equation;    fatigue;   

Others  :  1151430
DOI  :  10.1186/1471-2474-12-246

 received in 2011-04-29, accepted in 2011-10-28,  发布年份 2011

【 摘 要 】

Background

Age-related sarcopenia is a disease state of loss of muscle mass and strength that affects physical function and mobility leading to falls, fractures, and disability. The need for therapies to treat age-related sarcopenia has attracted intensive preclinical research. To facilitate the discovery of these therapies, we have developed a non-invasive rat muscle functional assay system to efficiently measure muscle force and evaluate the efficacy of drug candidates.

Methods

The lower leg muscles of anesthetized rats are artificially stimulated with surface electrodes on the knee holders and the heel support, causing the lower leg muscles to push isometric pedals that are attached to force transducers. We developed a stimulation protocol to perform a fatigability test that reveals functional muscle parameters like maximal force, the rate of fatigue, fatigue-resistant force, as well as a fatigable muscle force index. The system is evaluated in a rat aging model and a rat glucocorticoid-induced muscle loss model

Results

The aged rats were generally weaker than adult rats and showed a greater reduction in their fatigable force when compared to their fatigue-resistant force. Glucocorticoid treated rats mostly lost fatigable force and fatigued at a higher rate, indicating reduced force from glycolytic fibers with reduced energy reserves.

Conclusions

The involuntary contraction assay is a reliable system to assess muscle function in rodents and can be applied in preclinical research, including age-related sarcopenia and other myopathy.

【 授权许可】

   
2011 Chiu et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

Figure 10.

Figure 3.

【 参考文献 】

• [1]Theou O, Jones GR, Overend TJ, Kloseck M, Vandervoort AA: An exploration of the association between frailty and muscle fatigue. Appl Physiol Nutr Metab 2008, 33:651-665.
• [2]United Nations DoEaSA: WORLD POPULATION AGEING: 1950-2050. UNITED NATIONS PUBLICATIONS 2002. E.02.XIII.03
• [3]Bauer JM, Sieber CC: Sarcopenia and frailty: a clinician's controversial point of view. Exp Gerontol 2008, 43:674-678.
• [4]Lauretani F, Russo CR, Bandinelli S, Bartali B, Cavazzini C, Di Iorio A, Corsi AM, Rantanen T, Guralnik JM, Ferrucci L: Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol 2003, 95:1851-1860.
• [5]Reid KF, Naumova EN, Carabello RJ, Phillips EM, Fielding RA: Lower extremity muscle mass predicts functional performance in mobility-limited elders. J Nutr Health Aging 2008, 12:493-498.
• [6]Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA, Wallace RB: A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 1994, 49:M85-94.
• [7]Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA: Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001, 56:M146-156.
• [8]Schroeder ET, Castaneda-Sceppa C, Wang Y, Binder EF, Kawakubo M, Stewart Y, Storer T, Roubenoff R, Bhasin S, Yarasheski KE, et al.: Hormonal regulators of muscle and metabolism in aging (HORMA): design and conduct of a complex, double masked multicenter trial. Clin Trials 2007, 4:560-571.
• [9]Reuben DB, Siu AL: An objective measure of physical function of elderly outpatients. The Physical Performance Test. J Am Geriatr Soc 1990, 38:1105-1112.
• [10]Frontera WR, Reid KF, Phillips EM, Krivickas LS, Hughes VA, Roubenoff R, Fielding RA: Muscle fiber size and function in elderly humans: a longitudinal study. J Appl Physiol 2008, 105:637-642.
• [11]Behnke BJ, Delp MD, Dougherty PJ, Musch TI, Poole DC: Effects of aging on microvascular oxygen pressures in rat skeletal muscle. Respir Physiol Neurobiol 2005, 146:259-268.
• [12]Dinenno FA, Jones PP, Seals DR, Tanaka H: Limb blood flow and vascular conductance are reduced with age in healthy humans: relation to elevations in sympathetic nerve activity and declines in oxygen demand. Circulation 1999, 100:164-170.
• [13]Narici MV, Maganaris CN, Reeves ND, Capodaglio P: Effect of aging on human muscle architecture. J Appl Physiol 2003, 95:2229-2234.
• [14]Lexell J, Downham D: What is the effect of ageing on type 2 muscle fibres? J Neurol Sci 1992, 107:250-251.
• [15]Gao W, Reiser PJ, Coss CC, Phelps MA, Kearbey JD, Miller DD, Dalton JT: Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology 2005, 146:4887-4897.
• [16]Ohsawa Y, Hagiwara H, Nakatani M, Yasue A, Moriyama K, Murakami T, Tsuchida K, Noji S, Sunada Y: Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition. J Clin Invest 2006, 116:2924-2934.
• [17]Carlson ME, Hsu M, Conboy IM: Imbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cells. Nature 2008, 454:528-532.
• [18]Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, Gamradt M, ap Rhys CM, Holm TM, Loeys BL, et al.: Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007, 13:204-210.
• [19]Beitzel F, Sillence MN, Lynch GS: beta-Adrenoceptor signaling in regenerating skeletal muscle after beta-agonist administration. Am J Physiol Endocrinol Metab 2007, 293:E932-940.
• [20]Di Bari M, van de Poll-Franse LV, Onder G, Kritchevsky SB, Newman A, Harris TB, Williamson JD, Marchionni N, Pahor M: Antihypertensive medications and differences in muscle mass in older persons: the Health, Aging and Body Composition Study. J Am Geriatr Soc 2004, 52:961-966.
• [21]Stoch SA, Freidman EJ, Zhou Y, Bonilla J, Xu Y, Binkowitz B, Chodakewitz JA, Wagner JA: A 12-week pharmacokinetic (PK) and pharmacodynamic (PD) study of MK-0773 in healthy older men. Abstract from the Society for Endocrinology annual meeting, San Francisco 2008.
• [22]Pellegrino MA, D'Antona G, Bortolotto S, Boschi F, Pastoris O, Bottinelli R, Polla B, Reggiani C: Clenbuterol antagonizes glucocorticoid-induced atrophy and fibre type transformation in mice. Exp Physiol 2004, 89:89-100.
• [23]Shin YS, Fink H, Khiroya R, Ibebunjo C, Martyn J: Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression. Anesth Analg 2000, 91:322-328.
• [24]Ruff RL, Martyn D, Gordon AM: Glucocorticoid-induced atrophy is not due to impaired excitability of rat muscle. Am J Physiol 1982, 243:E512-521.
• [25]Cederna PS, Asato H, Gu X, van der Meulen J, Kuzon WM Jr, Carlson BM, Faulkner JA: Motor unit properties of nerve-intact extensor digitorum longus muscle grafts in youngand old rats. J Gerontol A Biol Sci Med Sci 2001, 56:B254-258.
• [26]Sugiura M, Kanda K: Progress of age-related changes in properties of motor units in the gastrocnemius muscle of rats. J Neurophysiol 2004, 92:1357-1365.
• [27]Carter CS, Cesari M, Ambrosius WT, Hu N, Diz D, Oden S, Sonntag WE, Pahor M: Angiotensin-converting enzyme inhibition, body composition, and physical performance in aged rats. J Gerontol A Biol Sci Med Sci 2004, 59:416-423.
• [28]Kovacheva EL, Hikim AP, Shen R, Sinha I, Sinha-Hikim I: Testosterone supplementation reverses sarcopenia in aging through regulation of myostatin, c-Jun NH2-terminal kinase, Notch, and Akt signaling pathways. Endocrinology 2010, 151:628-638.
• [29]Siriett V, Salerno MS, Berry C, Nicholas G, Bower R, Kambadur R, Sharma M: Antagonism of myostatin enhances muscle regeneration during sarcopenia. Mol Ther 2007, 15:1463-1470.
• [30]Maurissen JP, Marable BR, Andrus AK, Stebbins KE: Factors affecting grip strength testing. Neurotoxicol Teratol 2003, 25:543-553.
• [31]Kuhn PL, Petroulakis E, Zazanis GA, McKinnon RD: Motor function analysis of myelin mutant mice using a rotarod. Int J Dev Neurosci 1995, 13:715-722.
• [32]Faulkner JA, Brooks SV: An in situ single skeletal muscle model of contraction-induced injury: mechanistic interpretations. Basic and Applied Myology 1994, 4:6.
• [33]Lynch GS, Rodgers BJ, Williams DA: The effects of age and low-intensity endurance exercise on the contractile properties of single skinned fast- and slow-twitch skeletal muscle fibres. Growth Dev Aging 1993, 57:147-161.
• [34]Ashton-Miller JA, He Y, Kadhiresan VA, McCubbrey DA, Faulkner JA: An apparatus to measure in vivo biomechanical behavior of dorsi- and plantarflexors of mouse ankle. J Appl Physiol 1992, 72:1205-1211.
• [35]Cutlip RG, Stauber WT, Willison RH, McIntosh TA, Means KH: Dynamometer for rat plantar flexor muscles in vivo. Med Biol Eng Comput 1997, 35:540-543.
• [36]Geronilla KB, Miller GR, Mowrey KF, Wu JZ, Kashon ML, Brumbaugh K, Reynolds J, Hubbs A, Cutlip RG: Dynamic force responses of skeletal muscle during stretch-shortening cycles. Eur J Appl Physiol 2003, 90:144-153.
• [37]Giannesini B, Izquierdo M, Le Fur Y, Cozzone PJ, Fingerle J, Himber J, Kunnecke B, Von Kienlin M, Bendahan D: New experimental setup for studying strictly noninvasively skeletal muscle function in rat using 1Hmagnetic resonance (MR) imaging and 31P-MR spectroscopy. Magn Reson Med 2005, 54:1058-1064.
• [38]Burke RE, Levine DN, Tsairis P, Zajac FE: Physiological types and histochemical profiles in motor units of the cat gastrocnemius. J Physiol 1973, 234:723-748.
• [39]Korhonen MT, Cristea A, Alen M, Hakkinen K, Sipila S, Mero A, Viitasalo JT, Larsson L, Suominen H: Aging, muscle fiber type, and contractile function in sprint-trained athletes. J Appl Physiol 2006, 101:906-917.
• [40]Russ DW, Vandenborne K, Binder-Macleod SA: Factors in fatigue during intermittent electrical stimulation of human skeletal muscle. J Appl Physiol 2002, 93:469-478.
• [41]Clausen T, Overgaard K, Nielsen OB: Evidence that the Na+-K+ leak/pump ratio contributes to the difference in endurance between fast- and slowtwitch muscles. Acta Physiol Scand 2004, 180:209-216.
• [42]Cairns SP, Robinson DM, Loiselle DS: Double-sigmoid model for fitting fatigue profiles in mouse fast- and slow-twitch muscle. Exp Physiol 2008, 93:851-862.
• [43]Bickel CS, Slade JM, Warren GL, Dudley GA: Fatigability and variablefrequency train stimulation of human skeletal muscles. Phys Ther 2003, 83:366-373.
• [44]Binder-Macleod SA, Scott WB: Comparison of fatigue produced by various electrical stimulation trains. Acta Physiol Scand 2001, 172:195-203.
• [45]Thomas CK, Griffin L, Godfrey S, Ribot-Ciscar E, Butler JE: Fatigue of paralyzed and control thenar muscles induced by variable or constant frequency stimulation. J Neurophysiol 2003, 89:2055-2064.
• [46]Griffin L, Jun BG, Covington C, Doucet BM: Force output during fatigue with progressively increasing stimulation frequency. J Electromyogr Kinesiol 2008, 18:426-433.
• [47]Visser M, Kritchevsky SB, Goodpaster BH, Newman AB, Nevitt M, Stamm E, Harris TB: Leg muscle mass and composition in relation to lower extremity performance in men and women aged 70 to 79: the health, aging and body composition study. J Am Geriatr Soc 2002, 50:897-904.
• [48]Schakman O, Gilson H, Thissen JP: Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 2008, 197:1-10.
• [49]Buren J, Lai YC, Lundgren M, Eriksson JW, Jensen J: Insulin action and signalling in fat and muscle from dexamethasone-treated rats. Arch Biochem Biophys 2008, 474:91-101.